Revolutions Medical Completes Revision of Exclusive Rights to License Additional Patents on FDA Approved Breast Biopsy Localization System

/ Source: GlobeNewswire

CHARLESTON, S.C., Jan. 4, 2011 (GLOBE NEWSWIRE) -- Revolutions Medical Corporation ("Revolutions Medical" or the "Company") (OTCBB:RMCP) recently completed the reworking of a worldwide exclusive license with Traxyz, LLC for an image guided navigation system to convert over 50,000 conventional mammography systems for use as a high accuracy breast biopsies system (BBS). This BBS facilitates accurate and fast non-palpable lesions and micro calcification localization in the treatment of breast cancer.

A new agreement simplifies the licensing arrangement by providing for the direct licensing with the Traxyz, LLC, the original developer of the technology. This technology has already received 510K clearance by the FDA. 

It is a low-cost, stand-alone stereotactic image-based system which uses data from a pair of mammograms to enable radiologists to accurately position a localization needle or biopsy tool at the location of suspicious abnormalities in the patient's breast. Revolutions Medical believes that the BBS, preliminary called RevTrack, will offer significant advantages for the localization and biopsy of breast abnormalities. This represents another step in Revolutions Medical's mission statement 'to be committed to continually developing and distributing new products and tools to the medical industry, whether internally or through acquisitions. Its goals are to make health care safer and less expensive by reducing risks and cutting time and expenses.'

The BBS localization needle can be modified to use the Company's proprietary RevVac safety syringe technology. Additionally, one of the patents covering the stabilization technology can be used to further enhance the Company's MRI software tools by providing for a proprietary platform for image fusion between MRI and X-Ray. 

Approximately 4 million diagnostic procedures are performed annually worldwide to evaluate abnormalities detected during mammography screening. Revolutions Medical believes that this technology has the potential to be deployed in the vast majority of more than 50,000 mammography machines that are currently in use worldwide. 15,000 of the machines are in the U.S. 

"Revolutions Medical is committed to bring this new exciting product to the marketplace and I am very pleased to have this agreement concluded at the end of 2010, in accordance with our previous statements.  In the near future, by fusing our RevColor and Rev3D MRI technology with x-ray images, we believe there is a possibility of a multi-modal breast imaging technology, which could dramatically increase the accuracy of the detection of breast cancer," states Ron Wheet, CEO, Revolutions Medical Corporation.

About Revolutions Medical Corporation

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac Safety Syringe (FDA approved), safety blood drawing device, and the RevColorTM, RevDisplayTM and Rev3DTM software solutions and proprietary tools that are compatible with standard MRIs and standard Picture Archiving Computer Systems (PACS). The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

For additional information, please visit Revolutions Medical corporate website:

Investor Resource Center

CEO Ron Wheet Audio Interview:

RevVac Safety Syringe Demonstration Video:

RevColor MRI Video:

To be added to the Revolutions Medical investor email list, please email with RMCP in the subject line.

Become a RevMed fan and follow the Company on Facebook -- visit


The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

CONTACT: Revolutions Medical Corporation Investor Relations: Scott Key (843) 518-0437